KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer
Cancer Cell · 2025-08 · 43 (8) · 1530-1548.e9
DOI: 10.1016/j.ccell.2025.06.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2025-08. Verfasst von Ana Galan-Cobo und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, Carcinoma, Non-Small-Cell Lung, Protein Serine-Threonine Kinases, Lung Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Bill & Katie Weaver Charitable Trust, Cancer Prevention and Research Institute of Texas.
Abstract (Originalsprache)
KRAS mutations frequently co-occur with alterations in STK11/LKB1 and/or KEAP1, defining an aggressive subset of lung cancers resistant to immuno- and chemotherapy. While LKB1 loss is associated with vulnerability to DNA damage response-based therapies, the impact of KEAP1 alterations remains unknown. We demonstrate that KEAP1-NRF2 pathway drives a compensatory modulation of ATR-CHK1 signaling, enhancing vulnerability to ATR inhibitors (ATRi), particularly in the setting of increased replication stress associated with LKB1 loss. ATRi shows enhanced anti-tumor activity in LKB1 and/or KEAP1-deficient non-small cell lung cancer (NSCLC) models and synergizes with gemcitabine. ATRi also enhances antitumor immunity and mitigates the immunosuppressed phenotype of LKB1/KEAP1-deficient tumors. In the HUDSON trial, LKB1/KEAP1-deficient NSCLC patients demonstrate enhanced benefits to the ATRi ceralasertib plus durvalumab. These findings suggest that alterations in the KEAP1-NRF2 pathway and/or LKB1 are associated with enhanced sensitivity to ATRi and could serve as biomarkers for predicting response to ATRi combination regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.
- Early Oncology R&D, AstraZeneca, Cambridge, UK.
- Imaging Sciences, CPSS, AstraZeneca, Cambridge, UK.
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Förderung
- NCI NIH HHS
- Bill & Katie Weaver Charitable Trust
- Cancer Prevention and Research Institute of Texas
- Hebei Normal University of Science and Technology
- Cain Foundation
- Mark Foundation For Cancer Research
- University of Texas MD Anderson Cancer Center
- Yale SPORE in Lung Cancer
Zitieren
APA
Galan-Cobo, A., Vokes, N. I., Qian, Y., Molkentine, D., Ramkumar, K., Paula, A. G., Pisegna, M., McGrail, D. J., Poteete, A., Cho, S., Do, M. T., Karimi, A., Kong, Y., Solanki, A., Karmokar, A., Floc'h, N., Hughes, A., Sargeant, R., Young, L., …, & Heymach, J. V. (2025). KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell, 43(8), 1530-1548.e9. https://doi.org/10.1016/j.ccell.2025.06.011
Vancouver
Galan-Cobo A, Vokes NI, Qian Y, Molkentine D, Ramkumar K, Paula AG, et al. KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer Cell. 2025;43(8):1530-1548.e9. doi:10.1016/j.ccell.2025.06.011
BibTeX
@article{GalanCobo2025,
author = {Galan-Cobo, Ana and Vokes, Natalie I and Qian, Yu and Molkentine, David and Ramkumar, Kavya and Paula, Alvaro G and Pisegna, Marlese and McGrail, Daniel J and Poteete, Alissa and Cho, Sungnam and Do, Minh Truong and Karimi, Amirali and Kong, Yifan and Solanki, Anisha and Karmokar, Ankur and Floc'h, Nicolas and Hughes, Adina and Sargeant, Rebecca and Young, Lucy and Shen, Li and Kar, Gozde and Keshvani, Caezaan and Arrechedera, Claudio and Hernandez, Sharia and Schlacher, Katharina and Wang, Jing and Iyer, Sonia and Conway, James and Keddar, Mohamed Reda and Milo, Marta and de Toma, Ilario and Critchlow, Susan E and Barrett, J Carl and Cosaert, Jan and Lau, Alan and Valge-Archer, Viia and Byers, Lauren A and Barry, Simon T and Heymach, John V},
title = {KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer},
journal = {Cancer Cell},
year = {2025},
volume = {43},
number = {8},
pages = {1530--1548.e9},
doi = {10.1016/j.ccell.2025.06.011}
}
EUVIMED